Cancer Therapy

You have full text access to this OnlineOpen article

RNAi-mediated downregulation of urokinase plasminogen activator receptor and matrix metalloprotease-9 in human breast cancer cells results in decreased tumor invasion, angiogenesis and growth

  1. Sateesh Kunigal1,
  2. Sajani S. Lakka1,
  3. Christopher S. Gondi1,
  4. Norman Estes2,
  5. Jasti S. Rao1,3,†,*

Article first published online: 26 JUL 2007

DOI: 10.1002/ijc.22962

Issue

International Journal of Cancer

International Journal of Cancer

Volume 121, Issue 10, pages 2307–2316, 15 November 2007

Additional Information

How to Cite

Kunigal, S., Lakka, S. S., Gondi, C. S., Estes, N. and Rao, J. S. (2007), RNAi-mediated downregulation of urokinase plasminogen activator receptor and matrix metalloprotease-9 in human breast cancer cells results in decreased tumor invasion, angiogenesis and growth. Int. J. Cancer, 121: 2307–2316. doi: 10.1002/ijc.22962

Author Information

  1. 1

    Department of Cancer Biology and Pharmacology, University of Illinois College of Medicine at Peoria, Peoria, IL

  2. 2

    Department of Surgery, University of Illinois College of Medicine at Peoria, Peoria, IL

  3. 3

    Department of Neurosurgery, University of Illinois College of Medicine at Peoria, Peoria, IL

  1. †

    Fax: +309-671-3442.

*Department of Cancer Biology and Pharmacology, University of Illinois College of Medicine at Peoria, One Illini Drive, Peoria, IL 61605, USA

Publication History

  1. Issue published online: 25 SEP 2007
  2. Article first published online: 26 JUL 2007
  3. Manuscript Accepted: 30 MAY 2007
  4. Manuscript Received: 15 DEC 2006

Funded by

  • National Cancer Institute. Grant Numbers: CA 75557, CA 92393, CA 95058, CA 116708, N.I.N.D.S. NS47699, NS57529
  • Caterpillar, Inc
  • OSF Saint Francis, Inc., Peoria, IL

SEARCH

SEARCH BY CITATION

ARTICLE TOOLS

View Full Article (HTML) Get PDF (1237K)

References

  • 1
    Cottam DW, Rees RC. Regulation of matrix metalloproteinases: their role in tumor invasion and metastasis. Int J Oncol 1993; 2: 861–72.
  • 2
    Mignatti P, Robbins E, Rifkin DB. Tumor invasion through the human amniotic membrane: requirement for a proteinase cascade. Cell 1986; 47: 487–98.
  • 3
    Hooper JD, Clements JA, Quigley JP, Antalis TM. Type II transmembrane serine proteases. Insights into an emerging class of cell surface proteolytic enzymes. J Biol Chem 2001; 276: 857–60.
  • 4
    Dano K, Behrendt N, Brunner N, Ellis V, Ploug M, Pyke C. The urokinse receptor. Protein structure and role in plasminogen activation and cancer invasion. Fibrinolysis 1994; 8: 189–203.
  • 5
    Gondi CS, Lakka SS, Yanamandra N, Siddique K, Dinh DH, Olivero WC, Gujrati M, Rao JS. Expression of antisense uPAR and antisense uPA from a bicistronic adenoviral construct inhibits glioma cell invasion, tumor growth, and angiogenesis. Oncogene 2003; 22: 5967–75.
  • 6
    Pulukuri SM, Gondi CS, Lakka SS, Jutla A, Estes N, Gujrati M, Rao JS. RNA interference-directed knockdown of urokinase plasminogen activator and urokinase plasminogen activator receptor inhibits prostate cancer cell invasion. survival, and tumorigenicity in vivo. J Biol Chem 2005; 280: 36529–40.
  • 7
    Subramanian R, Gondi CS, Lakka SS, Jutla A, Rao JS. siRNA-mediated simultaneous downregulation of uPA and its receptor inhibits angiogenesis and invasiveness triggering apoptosis in breast cancer cells. Int J Oncol 2006; 28: 831–9.
  • 8
    Chapman HA, Wei Y, Simon DI, Waltz DA. Role of urokinase receptor and caveolin in regulation of integrin signaling. Thromb Haemost 1999; 82: 291–7.
  • 9
    Irigoyen JP, Munoz-Canoves P, Montero L, Koziczak M, Nagamine Y. The plasminogen activator system: biology and regulation. Cell Mol Life Sci 1999; 56: 104–32.
  • 10
    Rao NK, Shi GP, Chapman HA. Urokinase receptor is a multifunctional protein: influence of receptor occupancy on macrophage gene expression. J Clin Invest 1995; 96: 465–74.
  • 11
    Ruoslahti E. Integrins. J Clin Invest 1991; 87: 1–4.
  • 12
    Aguirre-Ghiso JA, Alonso DF, Farias EF, Gomez DE, Kier Joffe EB. Deregulation of the signaling pathways controlling urokinase production. Its relationship with the invasive phenotype. Eur J Biochem 1999; 263: 295–304.
    Direct Link:
  • 13
    Ma Z, Webb DJ, Jo M, Gonias SL. Endogenously produced urokinase-type plasminogen activator is a major determinant of the basal level of activated ERK/MAP kinase and prevents apoptosis in MDA-MB-231 breast cancer cells. J Cell Sci 2001; 114: 3387–96.
  • 14
    Nguyen DH, Hussaini IM, Gonias SL. Binding of urokinase-type plasminogen activator to its receptor in MCF-7 cells activates extracellular signal-regulated kinase 1 and 2 which is required for increased cellular motility. J Biol Chem 1998; 273: 8502–7.
  • 15
    Berger DH. Plasmin/plasminogen system in colorectal cancer. World J Surg 2002; 26: 767–71.
  • 16
    MacKay AR, Corbitt RH, Hartzler JL, Thorgeirsson UP. Basement membrane type IV collagen degradation: evidence for the involvement of a proteolytic cascade independent of metalloproteinases. Cancer Res 1990; 50: 5997–6001.
  • 17
    Sato H, Takino T, Okada Y, Cao J, Shinagawa A, Yamamoto E, Seiki M. A matrix metalloproteinase expressed on the surface of invasive tumour cells. Nature 1994; 370: 61–5.
  • 18
    Liotta LA, Steeg PS, Stetler-Stevenson WG. Cancer metastasis and angiogenesis: an imbalance of positive and negative regulation. Cell 1991; 64: 327–36.
  • 19
    Davies B, Miles DW, Happerfield LC, Naylor MS, Bobrow LG, Rubens RD, Balkwill FR. Activity of type IV collagenases in benign and malignant breast disease. Br J Cancer 1993; 67: 1126–31.
  • 20
    Davies B, Waxman J, Wasan H, Abel P, Williams G, Krausz T, Neal D, Thomas D, Hanby A, Balkwill F. Levels of matrix metalloproteases in bladder cancer correlate with tumor grade and invasion. Cancer Res 1993; 53: 5365–9.
  • 21
    Naylor MS, Stamp GW, Davies BD, Balkwill FR. Expression and activity of MMPS and their regulators in ovarian cancer. Int J Cancer 1994; 58: 50–6.
    Direct Link:
  • 22
    Hamdy FC, Fadlon EJ, Cottam D, Lawry J, Thurrell W, Silcocks PB, Anderson JB, Williams JL, Rees RC. Matrix metalloproteinase 9 expression in primary human prostatic adenocarcinoma and benign prostatic hyperplasia. Br J Cancer 1994; 69: 177–82.
  • 23
    Levy AT, Cioce V, Sobel ME, Garbisa S, Grigioni WF, Liotta LA, Stetler-Stevenson WG. Increased expression of the Mr 72,000 type IV collagenase in human colonic adenocarcinoma. Cancer Res 1991; 51: 439–44.
  • 24
    Kim ES, Kim MS, Moon A. TGF-beta-induced upregulation of MMP-2 and MMP-9 depends on p38 MAPK, but not ERK signaling in MCF10A human breast epithelial cells. Int J Oncol 2004; 25: 1375–82.
  • 25
    Rouyer N, Wolf C, Chenard MP, Rio MC, Chambon P, Bellocq JP, Basset P. Stromelysin-3 gene expression in human cancer: an overview. Invasion Metastasis 1994; 14: 269–75.
  • 26
    Tester AM, Ruangpanit N, Anderson RL, Thompson EW. MMP-9 secretion and MMP-2 activation distinguish invasive and metastatic sublines of a mouse mammary carcinoma system showing epithelial-mesenchymal transition traits. Clin Exp Metastasis 2000; 18: 553–60.
  • 27
    Lakka SS, Gondi CS, Dinh DH, Olivero WC, Gujrati M, Rao VH, Sioka C, Rao JS. Specific interference of uPAR and MMP-9 gene expression induced by double-stranded RNA results in decreased invasion, tumor growth and angiogenesis in gliomas. J Biol Chem 2005; 280: 21882–92.
  • 28
    Anderson WF. Excitement in gene therapy! Hum Gene Ther 2001; 12: 1483–4.
  • 29
    Graham FL, Prevec L. Manipulation of adenovirus vectors. In: MurrayEJ, ed. Methods in molecular biology. Clifton, NJ: The Humana Press, 1991. 109–27.
  • 30
    Lakka SS, Jasti SL, Gondi C, Boyd D, Chandrasekar N, Dinh DH, Olivero WC, Gujrati M, Rao JS. Downregulation of MMP-9 in ERK-mutated stable transfectants inhibits glioma invasion in vitro. Oncogene 2002; 21: 5601–8.
  • 31
    McManus MT, Sharp PA. Gene silencing in mammals by small interfering RNAs. Nat Rev Genet 2002; 3: 737–47.
  • 32
    Andreasen PA, Kjoller L, Christensen L, Duffy MJ. The urokinase-type plasminogen activator system in cancer metastasis: a review. Int J Cancer 1997; 72: 1–22.
    Direct Link:
  • 33
    Duffy MJ. Proteases as prognostic markers in cancer. Clin Cancer Res 1996; 2: 613–8.
  • 34
    Foekens JA, Peters HA, Look MP, Portengen H, Schmitt M, Kramer MD, Brunner N, Janicke F, Meijer-van Gelder ME, Henzen-Logmans SC, van Putten WL, Klijn JG. The urokinase system of plasminogen activation and prognosis in 2780 breast cancer patients. Cancer Res 2000; 60: 636–43.
  • 35
    Ghosh S, Elleroboer SM, Wu Y, Stack MD. Tumor-cell mediated proteolysis: regulatory mechanisms and functional consequences. Fibr Proteolysis 2000; 14: 87.
  • 36
    Rabbani SA, Mazar AP. The role of the plasminogen activation system in angiogenesis and metastasis. Surg Oncol Clin N Am 2001; 10: 393–415.
  • 37
    McCawley LJ, Matrisian LM. Matrix metalloproteinases: they're not just for matrix anymore! Curr Opin Cell Biol 2001; 13: 534–40.
  • 38
    Patterson BC, Sang QA. Angiostatin-converting enzyme activities of human matrilysin (MMP-7) and gelatinase B/type IV collagenase (MMP-9). J Biol Chem 1997; 272: 28823–5.
  • 39
    Ribatti D, Leali D, Vacca A, Giuliani R, Gualandris A, Roncali L, Nolli ML, Presta M. In vivo angiogenic activity of urokinase: role of endogenous fibroblast growth factor-2. J Cell Sci 1999; 112(Part 23): 4213–21.
  • 40
    Bergers G, Brekken R, McMahon G, Vu TH, Itoh T, Tamaki K, Tanzawa K, Thorpe P, Itohara S, Werb Z, Hanahan D. Matrix metalloproteinase-9 triggers the angiogenic switch during carcinogenesis. Nat Cell Biol 2000; 2: 737–44.
  • 41
    O'Mahony CA, Seidel A, Albo D, Chang H, Tuszynski GP, Berger DH. Angiostatin generation by human pancreatic cancer. J Surg Res 1998; 77: 55–8.
  • 42
    Brinckerhoff CE, Matrisian LM. Matrix metalloproteinases: a tail of a frog that became a prince. Nat Rev Mol Cell Biol 2002; 3: 207–14.
  • 43
    Stamenkovic I. Matrix metalloproteinases in tumor invasion and metastasis. Semin Cancer Biol 2000; 10: 415–33.
  • 44
    Liotta LA, Tryggvason K, Garbisa S, Hart I, Foltz CM, Shafie S. Metastatic potential correlates with enzymatic degradation of basement membrane collagen. Nature 1980; 284: 67–8.
  • 45
    Azzam HS, Arand G, Lippman ME, Thompson EW. Association of MMP-2 activation potential with metastatic progression in human breast cancer cell lines independent of MMP-2 production. J Natl Cancer Inst 1993; 85: 1758–64.
  • 46
    Yu Q, Stamenkovic I. Cell surface-localized matrix metalloproteinase-9 proteolytically activates TGF-beta and promotes tumor invasion and angiogenesis. Genes Dev 2000; 14: 163–76.
  • 47
    Yu Q, Grammatikakis N, Toole BP. Expression of multiple CD44 isoforms in the apical ectodermal ridge of the embryonic mouse limb. Dev Dyn 1996; 207: 204–14.
    Direct Link:
  • 48
    Okamoto I, Kawano Y, Tsuiki H, Sasaki J, Nakao M, Matsumoto M, Suga M, Ando M, Nakajima M, Saya H. CD44 cleavage induced by a membrane-associated metalloprotease plays a critical role in tumor cell migration. Oncogene 1999; 18: 1435–46.
  • 49
    Kobayashi H, Suzuki M, Kanayama N, Nishida T, Takigawa M, Terao T. CD44 stimulation by fragmented hyaluronic acid induces upregulation of urokinase-type plasminogen activator and its receptor and subsequently facilitates invasion of human chondrosarcoma cells. Int J Cancer 2002; 102: 379–89.
    Direct Link:
  • 50
    Laube F. Co-localization of CD44 and urokinase-type plasminogen activator on the surface of human melanoma cells. Anticancer Res 2000; 20: 5045–8.
  • 51
    Paddison PJ, Hannon GJ. RNA interference: the new somatic cell genetics? Cancer Cell 2002; 2: 17–23.
  • 52
    Evans CP, Elfman F, Parangi S, Conn M, Cunha G, Shuman MA. Inhibition of prostate cancer neovascularization and growth by urokinase-plasminogen activator receptor blockade. Cancer Res 1997; 57: 3594–9.
  • 53
    Guo Y, Higazi AA, Arakelian A, Sachais BS, Cines D, Goldfarb RH, Jones TR, Kwaan H, Mazar AP, Rabbani SA. A peptide derived from the nonreceptor binding region of urokinase plasminogen activator (uPA) inhibits tumor progression and angiogenesis and induces tumor cell death in vivo. FASEB J 2000; 14: 1400–10.
  • 54
    Li H, Lu H, Griscelli F, Opolon P, Sun LQ, Ragot T, Legrand Y, Belin D, Soria J, Soria C, Perricaudet M, Yeh P. Adenovirus-mediated delivery of a uPA/uPAR antagonist suppresses angiogenesis-dependent tumor growth and dissemination in mice. Gene Ther 1998; 5: 1105–13.
  • 55
    Mishima K, Mazar AP, Gown A, Skelly M, Ji XD, Wang XD, Jones TR, Cavenee WK, Huang HJ. A peptide derived from the non-receptor-binding region of urokinase plasminogen activator inhibits glioblastoma growth and angiogenesis in vivo in combination with cisplatin. Proc Natl Acad Sci USA 2000; 97: 8484–9.
  • 56
    Mazar AP, Henkin J, Goldfarb RH. The urokinase plasminogen activator system in cancer: implications for tumor angiogenesis and metastasis. Angiogenesis 1999; 3: 15–32.
  • 57
    Dano K, Andreasen PA, Grondahl-Hansen J, Kristensen P, Nielsen LS, Skriver L. Plasminogen activators, tissue degradation, and cancer. Adv Cancer Res 1985; 44: 139–266.
  • 58
    Plesner T, Behrendt N, Ploug M. Structure, function and expression on blood and bone marrow cells of the urokinase-type plasminogen activator receptor, uPAR. Stem Cells 1997; 15: 398–408.
    Direct Link:
  • 59
    Kondraganti S, Mohanam S, Chintala SK, Kin Y, Jasti SL, Nirmala C, Lakka SS, Adachi Y, Kyritsis AP, Ali-Osman F, Sawaya R, Fuller GN, et al. Selective suppression of matrix metalloproteinase-9 in human glioblastoma cells by antisense gene transfer impairs glioblastoma cell invasion. Cancer Res 2000; 60: 6851–5.
  • 60
    Lakka SS, Rajan M, Gondi C, Yanamandra N, Chandrasekar N, Jasti SL, Adachi Y, Siddique K, Gujrati M, Olivero W, Dinh DH, Kouraklis G, et al. Adenovirus-mediated expression of antisense MMP-9 in glioma cells inhibits tumor growth and invasion. Oncogene 2002; 21: 8011–19.
  • 61
    Sternlicht MD, Bergers G. Matrix metalloproteinases as emerging targets in anticancer therapy: status and prospects. Emerg Ther Targets 2000; 4: 609–33.
  • 62
    Kin Y, Chintala SK, Go Y, Sawaya R, Mohanam S, Kyritsis AP, Rao JS. A novel role for the urokinase-type plasminogen activator receptor in apoptosis of malignant gliomas. Int J Oncol 2000; 17: 61–5.
  • 63
    Johnson GL, Lapadat R. Mitogen-activated protein kinase pathways mediated by ERK. J. NK, and p38 protein kinases. Science 2002; 298: 1911–12.
  • 64
    Aguirre-Ghiso JA, Estrada Y, Liu D, Ossowski L. ERK(MAPK) activity as a determinant of tumor growth and dormancy; regulation by p38(SAPK). Cancer Res 2003; 63: 1684–95.
  • 65
    Mueller H, Flury N, Eppenberger-Castori S, Kueng W, David F, Eppenberger U. Potential prognostic value of mitogen-activated protein kinase activity for disease-free survival of primary breast cancer patients. Int J Cancer 2000; 89: 384–8.
    Direct Link:
  • 66
    Bonni A, Brunet A, West AE, Datta SR, Takasu MA, Greenberg ME. Cell survival promoted by the Ras-MAPK signaling pathway by transcription-dependent and -independent mechanisms. Science 1999; 286: 1358–62.
  • 67
    Xia Z, Dickens M, Raingeaud J, Davis RJ, Greenberg ME. Opposing effects of ERK and JNK-p38 MAP kinases on apoptosis. Science 1995; 270: 1326–31.
  • 68
    Dent P, Grant S. Pharmacologic interruption of the mitogen-activated extracellular-regulated kinase/mitogen-activated protein kinase signal transduction pathway: potential role in promoting cytotoxic drug action. Clin Cancer Res 2001; 7: 775–83.
  • 69
    Romerio F, Zella D. MEK and ERK inhibitors enhance the anti-proliferative effect of interferon-alpha2b. FASEB J 2002; 16: 1680–2.
  • 70
    Rao JS. Molecular mechanisms of glioma invasiveness: the role of proteases. Nat Rev Cancer 2003; 3: 489–501.
View Full Article (HTML) Get PDF (1237K)